Tumour control probability derived from dose distribution in homogeneous and heterogeneous models: Assuming similar pharmacokinetics, 125Sn 177Lu is superior to 90Y 177Lu in peptide receptor radiotherapy

Walrand, Stéphan;Hanin, François-Xavier;Pauwels, Stanislas;Jamar, François
(2012) Physics in Medicine and Biology — Vol. 57, n° 13, p. 4263-4275 (2012)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 1.92 MB
Request a copy

Details

Authors
  • Walrand, Stéphan
    Author
  • Hanin, François-XavierUCLouvain
    Author
  • Pauwels, StanislasUCLouvain
    Author
  • Jamar, FrançoisUCLouvain
    Author
Abstract
Clinical trials on <sup>177</sup>Lu <sup>90</sup>Y therapy used empirical activity ratios. Radionuclides (RN) with larger beta maximal range could favourably replace <sup>90</sup>Y. Our aim is to provide RN dose-deposition kernels and to compare the tumour control probability (TCP) of RN combinations. Dose kernels were derived by integration of the mono-energetic beta-ray dose distributions (computed using Monte Carlo) weighted by their respective beta spectrum. Nine homogeneous spherical tumours (125mm in diameter) and four spherical tumours including a lattice of cold, but alive, spheres (1, 3, 5, 7mm in diameter) were modelled. The TCP for <sup>93</sup>Y, <sup>90</sup>Y and <sup>125</sup>Sn in combination with <sup>177</sup>Lu in variable proportions (that kept constant the renal cortex biological effective dose) were derived by 3D dose kernel convolution. For a mean tumour-absorbed dose of 180 Gy, 2mm homogeneous tumours and tumours including 3mm diameter cold alive spheres were both well controlled (TCP > 0.9) using a 7525% combination of <sup>177</sup>Lu and <sup>90</sup>Y activity. However, <sup>125</sup>Sn <sup>177</sup>Lu achieved a significantly better result by controlling 1mm-homogeneous tumour simultaneously with tumours including 5mm diameter cold alive spheres. Clinical trials using RN combinations should use RN proportions tuned to the patient dosimetry. <sup>125</sup>Sn production and its coupling to somatostatin analogue appear feasible. Assuming similar pharmacokinetics <sup>125</sup>Sn is the best RN for combination with <sup>177</sup>Lu in peptide receptor radiotherapy justifying pharmacokinetics studies in rodent of <sup>125</sup>Sn-labelled somatostatin analogues. © 2012 Institute of Physics and Engineering in Medicine.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Walrand, S., Hanin, F.-X., Pauwels, S., & Jamar, F. (2012). Tumour control probability derived from dose distribution in homogeneous and heterogeneous models: Assuming similar pharmacokinetics, 125Sn 177Lu is superior to 90Y 177Lu in peptide receptor radiotherapy. Physics in Medicine and Biology, 57(13), 4263-4275. https://doi.org/10.1088/0031-9155/57/13/4263 (Original work published 2012)